CompletedNCT00111189
About this title
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
Read the official source — NCT00111189Official study titleA Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States, Costa Rica, Mexico, + 6 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT01617187
What is this study about?This study evaluated the safety and effectiveness of Asenapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT00644800
About this title
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
Read the official source — NCT00644800Official study titleAn Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis
This study has finished and is no longer accepting participants.
Multiple locations, including FortalezaSchizophrenia, BipolarityMedication studyAges 18–55
- Countries
- Brazil
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00240708
About this title
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
Read the official source — NCT00240708Official study titleA Parallel-Group Comparative Open-Label Study of Long-Acting Injectible Risperidone Versus Risperidone Tablets in Patients With Schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 20+
- Countries
- Sponsor
- Janssen Pharmaceutical K.K.
CompletedNCT05586789
What is this study about?This study evaluated the safety and effectiveness of Ranquilon for people with anxiety.
This study has finished and is no longer accepting participants.
Multiple locations, including Engel'sAdjustment disorder, AnxietyMedication studyAges 18–70
- Countries
- Russia
- Sponsor
- Valenta Pharm JSC
CompletedNCT00236444
About this title
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
Read the official source — NCT00236444Official study titleRisperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders.
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 5–17
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT06254612
What is this study about?Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
CompletedNCT00650429
About this title
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00650429Official study titleZiprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study
This study has finished and is no longer accepting participants.
Multiple locations, including MonterreySchizophreniaMedication studyAges 18–70
- Countries
- Mexico
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
TerminatedNCT00645229
What is this study about?This study evaluates the safety and effectiveness of Ziprasidone for people with schizophrenia.
This study ended early.
In LisbonSchizophreniaMedication studyAges 18–60
- Countries
- Portugal
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT01640080
What is this study about?This study evaluated the effectiveness of Esketamine for people with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including DaveDepressionMedication studyAges 18–64
- Countries
- Belgium, Germany, Poland
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT00210769
About this title
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
Read the official source — NCT00210769Official study titleOpen-label Extension of A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Extended Release OROS� Paliperidone (6 and 12 mg/Day) and Olanzapine (10 mg/Day), in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT04115319
What is this study about?Researchers compared SEP363856 and quetiapine XR, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–65
- Countries
- United States, Romania, Russia, + 1 other
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
